In Vivo Antitumor Activity of 5-Fluorocytosine on Human Colorectal Carcinoma Cells Genetically Modified to Express Cytosine Deaminase

Cancer Research

Volumn 53, Issue 19, 1993, Pages 4619-4626

  Huber, Brian E ^a   Austin, Elizabeth A ^a   Good, Steven S ^a   Knick, Vincent C ^a   Tibbels, Stephen ^a   Richards, Cynthia A ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE DEAMINASE; DNA; FLUCYTOSINE; FLUOROURACIL; THYMIDINE;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DEATH; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT; WEIGHT REDUCTION;

ANIMAL; CELL DIVISION; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FEMALE; FLUCYTOSINE; FLUOROURACIL; HUMAN; KINETICS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NUCLEOSIDE DEAMINASES; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0027496518     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Mandell, G.L., and Sande, M.A. Antimicrobial agents; penicillins and cephalosporins, In: L.S. Goodman and A.G. Gilmans (eds.), The Pharmacological Basis of Therapeutics Ed. 6, pp. 1126-1161. New York: MacMillian Publishing Co., 1980.
2. Whitley, R., and Gnann, J.W., Jr. Acyclovir: a decade later. N. Engl. J. Med., 327: 782-789, 1992.
3. Ashe, W.D., Jr., and Van Reken, D.E. 5-Fluorocytosine: a brief review. Clin. Pediatr., 16: 364-366, 1977.
4. Gunderson, L.L., Beart, R.W., and O'Connell, M.J. Current issues in the treatment of colorectal cancer. CRC Crit. Rev. Oncol. Hematol., 6: 223-260.
5. Abbruzzese, J.L., and Levin, B. Treatment of advanced colorectal cancer. Hematol. Oncol. Clin. North Am., 3: 135-153, 1989.
6. Bleiberg, H. Treatment of advanced colorectal cancer. Anticancer Res., 9: 1013-1015, 1989.
7. Huber, B.E., Richards, C.A., and Krenitsky, T.A. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc. Natl. Acad. Sci. USA, 88: 8039-8043, 1991.
8. Richards, C.A., and Huber, B.E. Generation of a transgenic model for retrovirus-mediated gene therapy for hepatocellular carcinoma is thwarted by the lack of trans-gene expression. Hum. Gene Then, 4: 143-150, 1993.
9. Austin, E.A., and Huber, B.E. A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of E. coli cytosine deaminase. Mol. Pharmacol., 43: 380-387, 1993.
10. Marquardt, D.W., and Siam, J. An algorithm for least square estimation of non-linear parameters. J. Soc. Indust. Appl. Math., 11: 431-441, 1963.
11. Huber, B.E., and Brown, N.A. 12-0-Tetradecanoylphorbol-13-acetate actions on macromolecular synthesis, ornithine decarboxylase, and cellular differentiation of the rat embryonic visceral yolk sac in culture. Cancer Res., 43: 5552-5559, 1983.
12. Guide for the Care and Use of Laboratory Animals. Revised 1985, prepared by the Committee on the Care and Use of Laboratory Animals, United States Department of Health and Human Services. NIH Publications No. 86-23. Washington, DC: United States Government Printing Office, 1988.
13. Windholz, M. (ed.). The Merck Index, Ed. 9, p. 534. Rahway, NJ: Merck and Co., Inc., 1976.
14. Andriole, G.L., Mule, J.J., Hasen, C.T., Linehan, W.M., and Rosenberg, S.A. Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice. J. Immunol., 135: 2911-2913, 1985.